Apellis posts results of Phase 3 extension study of pegcetacoplan in geographic atrophy
The study enrolled 792 participants and completed primary data collection on September 5, 2025. Results were first posted on ClinicalTrials.gov on October 28, 2026.
Primary source
ClinicalTrials.gov results record, October 28, 2026
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Read the source: An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation